IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (1195)	8/9/1997 10:40:00 PM
From: scaram(o)uche	of 1762

Max: Yup, the Navy study is why I popped into the thread. I had sold my shares at market open on the day of the advisory committee meeting (no boos or hisses from the gallery, please). I figured that it would be awhile before CD40L-related news surfaced. I was wrong. I saw the press release last week, went to the PNAS site, and used the market weakness yesterday to buy into calls for both Idec and Biogen. My question about the topo inhibitor was designed to find frosting on the cake. ;-) I've followed the CD40L work at Idec since it was licensed. I was recently V.P. Product Development at a reagents company, and we got an early opportunity to work with Noelle's antibody (MR1) against mouse gp39. I was blown away at how reproducibly we could induce antigen on the surface of activated T cells, but only after exquisite attempts to remove all B cells. If there was any B cell contamination of the prep whatsoever, we couldn't induce gp39 expression. That gave me a personal feel for the power of the gp39/CD40 interaction. When I saw the MR1 results from Noelle's lab with the collagen-induced arthritis model, I was hooked. Cheers! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next